ArticleNutrition & diabetes2026
Redox and bioenergetic modulation by plumbagin attenuated neuropathic allodynia in mice with diet-induced diabetes.
Article in Nutrition & diabetes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPainful diabetic neuropathy represents a substantial health burden, afflicting approximately 30% of individuals with diabetes. Currently available neuropathic pain medications exhibit only limited efficacy, are associated with significant adverse effects, and often result in poor patient adherence. The need for more effective neuropathic pain treatments in diabetic patients remains critical. This study aimed to evaluate the potential pain-relieving effects of plumbagin, a naturally occurring naphthoquinone, in a mouse model of persistent neuropathic pain associated with diet-induced type 2 diabetes.
methodsMale C57BL/6 J mice were fed a high-fat diet for eight weeks to induce type 2 diabetes. Pain-like behaviors were assessed using the von Frey test for mechanical allodynia and the acetone test for cold allodynia. The underlying mechanisms related to redox status and bioenergetics were explored using both in vivo and in vitro approaches.
resultsChronic administration of plumbagin not only alleviated established mechanical and cold allodynia in mice with type 2 diabetes but also delayed the onset of neuropathic pain under a preventive regimen at lower doses. While plumbagin did not impact on metabolic characteristics of diabetic mice, it corrected mitochondrial bioenergetic deficits in dorsal root ganglion neurons, alleviated oxidative stress in pain-related tissues, and enhanced both sciatic nerve conduction velocity and blood flow. Importantly, the analgesic effects of plumbagin were found to be modulated through pharmacological manipulation of mitochondrial bioenergetic function and redox balance.
conclusionsThese findings demonstrate the analgesic activity of plumbagin in mice with diet-induced type 2 diabetes, an effect that is mechanistically linked to its capacity to enhance mitochondrial bioenergetics and attenuate oxidative stress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.